The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 3

Sensitivity analyses based on various exclusion criteria for DCR.

Excluded trial	No. of trials	No. of patients	Experimental group	Control group	RR (95% CI)	value for RR	(%)	value for heterogeneity
Cortot (2020)	5	554	314	240	1.12 [0.97, 1.29]	>0.05	83	<0.01
Fukuda (2019)	5	732	421	311	1.12 [0.97, 1.29]	>0.05	85	<0.01
Kitagawa (2019)	5	757	435	322	1.16 [0.99, 1.35]	>0.05	86	<0.01
Niho (2012)	5	597	324	273	1.09 [0.96, 1.23]	>0.05	73	<0.01
Saito (2019)	5	548	329	219	1.18 [1.05, 1.32]	<0.01	45	<0.01
Seto (2014)	5	620	366	254	1.15 [0.92, 1.43]	>0.05	87	<0.01